Toward Next-Generation Propellants: Assessing Lung Deposition of Beclometasone Dipropionate, Formoterol, and Glycopyrrolate Formulated with HFA-152a Using Functional Respiratory Imaging. (PubMed, J Aerosol Med Pulm Drug Deliv) - Jul 17, 2026 - "Reformulation of the BDP/FF/GB pMDI with the low-GWP propellant HFA-152a preserved total and regional lung deposition characteristics relative to the current HFA-134a formulation. These findings support the maintenance of deposition performance while enabling a substantial reduction in environmental impact, reinforcing the potential of HFA-152a as a next-generation propellant for carbon minimal pMDI therapies."
Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
|
|
Angelo Matturro; Diego González-Segura; Erika Cuoghi; Federica Sandri; Gianluigi Poli; Hosein Sadafi; Navid Monshi Tousi; Sara Panigone
|